Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$111.29
+0.1%
$105.67
$75.56
$139.13
$5.55B0.51637,793 shs618,133 shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$54.16
-6.0%
$54.03
$30.04
$71.13
$5.24B1.83.23 million shs3.10 million shs
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$13.80
-1.4%
$13.85
$10.60
$38.12
$1.47B0.26651,256 shs676,909 shs
Nuvalent, Inc. stock logo
NUVL
Nuvalent
$74.67
-0.5%
$78.76
$55.53
$113.51
$5.41B1.3509,641 shs295,563 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+1.76%+6.90%-0.51%+2.57%+28.97%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-3.58%+3.93%-11.58%+46.73%+20.36%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-1.06%+7.78%+3.40%-5.85%-24.12%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-1.35%+0.08%-10.06%-1.15%+4.82%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
4.7797 of 5 stars
4.51.00.04.53.74.20.6
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
3.7905 of 5 stars
4.33.00.00.02.83.30.6
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.2707 of 5 stars
3.52.00.00.02.32.50.0
Nuvalent, Inc. stock logo
NUVL
Nuvalent
3.1539 of 5 stars
4.51.00.00.02.43.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
3.07
Buy$178.0059.94% Upside
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.50
Moderate Buy$71.6032.20% Upside
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.91
Moderate Buy$40.55193.81% Upside
Nuvalent, Inc. stock logo
NUVL
Nuvalent
3.08
Buy$118.9159.25% Upside

Current Analyst Ratings Breakdown

Latest EWTX, NUVL, AXSM, and CRSP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$40.00 ➝ $30.00
8/19/2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$112.00
8/8/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$48.00 ➝ $49.00
8/7/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$65.00 ➝ $80.00
8/6/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$42.00 ➝ $56.00
8/5/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$173.00 ➝ $176.00
8/5/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$184.00 ➝ $189.00
8/5/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$82.00
8/5/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$38.00 ➝ $42.00
8/4/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$150.00
7/30/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageStrong-Buy$46.00
(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$385.69M14.40N/AN/A$1.46 per share76.23
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$37.31M132.02N/AN/A$18.81 per share2.88
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/A$5.59 per shareN/A
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/A$13.03 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$287.22M-$5.07N/A39.46N/A-49.88%-283.22%-33.06%N/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$366.25M-$5.43N/AN/AN/A-1,229.43%-20.05%-17.09%11/4/2025 (Estimated)
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$133.81M-$1.55N/AN/AN/AN/A-30.65%-29.18%11/6/2025 (Estimated)
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$260.76M-$4.90N/AN/AN/AN/A-32.58%-30.14%N/A

Latest EWTX, NUVL, AXSM, and CRSP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$0.42-$0.34+$0.08-$0.34N/AN/A
8/7/2025Q2 2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$1.27-$1.31-$0.04-$1.39N/AN/A
8/4/2025Q2 2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 million
8/4/2025Q2 2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.47-$1.29+$0.18-$2.40$6.44 million$0.89 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/AN/A
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
1.66
1.57
1.51
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A
16.61
16.61
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
28.87
28.87
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/A
13.57
13.57

Institutional Ownership

CompanyInstitutional Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
Nuvalent, Inc. stock logo
NUVL
Nuvalent
97.26%

Insider Ownership

CompanyInsider Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
22.40%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
4.10%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
23.20%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
10.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38049.90 million38.72 millionOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
46090.95 million87.22 millionOptionable
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
60105.35 million80.91 millionOptionable
Nuvalent, Inc. stock logo
NUVL
Nuvalent
4072.11 million64.75 millionOptionable

Recent News About These Companies

Wedbush Forecasts Nuvalent's Q3 Earnings (NASDAQ:NUVL)
Nuvalent (NUVL) Gets a Buy from Goldman Sachs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$111.29 +0.16 (+0.14%)
Closing price 04:00 PM Eastern
Extended Trading
$112.00 +0.70 (+0.63%)
As of 06:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$54.16 -3.43 (-5.96%)
Closing price 04:00 PM Eastern
Extended Trading
$54.22 +0.06 (+0.10%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Edgewise Therapeutics stock logo

Edgewise Therapeutics NASDAQ:EWTX

$13.80 -0.20 (-1.43%)
Closing price 04:00 PM Eastern
Extended Trading
$13.52 -0.28 (-1.99%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Nuvalent stock logo

Nuvalent NASDAQ:NUVL

$74.67 -0.34 (-0.45%)
Closing price 04:00 PM Eastern
Extended Trading
$74.70 +0.03 (+0.04%)
As of 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.